JP2018525462A5 - - Google Patents

Download PDF

Info

Publication number
JP2018525462A5
JP2018525462A5 JP2017566754A JP2017566754A JP2018525462A5 JP 2018525462 A5 JP2018525462 A5 JP 2018525462A5 JP 2017566754 A JP2017566754 A JP 2017566754A JP 2017566754 A JP2017566754 A JP 2017566754A JP 2018525462 A5 JP2018525462 A5 JP 2018525462A5
Authority
JP
Japan
Prior art keywords
polymer
alkyl
independently
formula
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017566754A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018525462A (ja
JP6914860B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/037166 external-priority patent/WO2017003668A1/en
Publication of JP2018525462A publication Critical patent/JP2018525462A/ja
Publication of JP2018525462A5 publication Critical patent/JP2018525462A5/ja
Priority to JP2021116707A priority Critical patent/JP7150945B2/ja
Application granted granted Critical
Publication of JP6914860B2 publication Critical patent/JP6914860B2/ja
Priority to JP2022154411A priority patent/JP7708728B2/ja
Priority to JP2025038440A priority patent/JP2025100542A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017566754A 2015-07-01 2016-06-13 カチオン性粘液酸ポリマー系デリバリーシステム Active JP6914860B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021116707A JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム
JP2022154411A JP7708728B2 (ja) 2015-07-01 2022-09-28 カチオン性粘液酸ポリマー系デリバリーシステム
JP2025038440A JP2025100542A (ja) 2015-07-01 2025-03-11 カチオン性粘液酸ポリマー系デリバリーシステム

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187366P 2015-07-01 2015-07-01
US62/187,366 2015-07-01
PCT/US2016/037166 WO2017003668A1 (en) 2015-07-01 2016-06-13 Cationic mucic acid polymer-based delivery systems

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021116707A Division JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム

Publications (3)

Publication Number Publication Date
JP2018525462A JP2018525462A (ja) 2018-09-06
JP2018525462A5 true JP2018525462A5 (cg-RX-API-DMAC7.html) 2019-06-13
JP6914860B2 JP6914860B2 (ja) 2021-08-04

Family

ID=57609004

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017566754A Active JP6914860B2 (ja) 2015-07-01 2016-06-13 カチオン性粘液酸ポリマー系デリバリーシステム
JP2021116707A Active JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム
JP2022154411A Active JP7708728B2 (ja) 2015-07-01 2022-09-28 カチオン性粘液酸ポリマー系デリバリーシステム
JP2025038440A Pending JP2025100542A (ja) 2015-07-01 2025-03-11 カチオン性粘液酸ポリマー系デリバリーシステム

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021116707A Active JP7150945B2 (ja) 2015-07-01 2021-07-14 カチオン性粘液酸ポリマー系デリバリーシステム
JP2022154411A Active JP7708728B2 (ja) 2015-07-01 2022-09-28 カチオン性粘液酸ポリマー系デリバリーシステム
JP2025038440A Pending JP2025100542A (ja) 2015-07-01 2025-03-11 カチオン性粘液酸ポリマー系デリバリーシステム

Country Status (6)

Country Link
US (4) US10287401B2 (cg-RX-API-DMAC7.html)
EP (2) EP3317323B1 (cg-RX-API-DMAC7.html)
JP (4) JP6914860B2 (cg-RX-API-DMAC7.html)
CN (2) CN107922609B (cg-RX-API-DMAC7.html)
ES (2) ES2980216T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017003668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems
US20190381188A1 (en) * 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles For Crossing The Blood Brain Barrier And Methods Of Treatment Using The Same
CN113905786A (zh) * 2019-05-29 2022-01-07 国立大学法人东京工业大学 复合物、药物、癌症治疗剂、试剂盒和缀合物
WO2021113643A2 (en) 2019-12-04 2021-06-10 Dantari, Inc. Methods and compositions for synthesis of therapeutic nanoparticles
JP7343874B2 (ja) * 2019-12-26 2023-09-13 株式会社島津製作所 データ処理方法及びデータ処理装置
EP4691490A1 (en) 2023-03-31 2026-02-11 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
ES2064101T3 (es) 1990-04-02 1995-01-16 Pfizer Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
JPH06503095A (ja) 1991-05-29 1994-04-07 ファイザー・インコーポレーテッド 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5936079A (en) 1992-04-06 1999-08-10 Alton Ochsner Medical Foundation Oligonucleotide which binds to a chromosomal binding site for p53 protein
EP0654024A1 (en) 1992-08-06 1995-05-24 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US6610832B1 (en) 1995-03-23 2003-08-26 Biopure Corporation Preserving a hemoglobin blood substitute with a transparent overwrap
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5693631A (en) 1995-05-30 1997-12-02 Buckman Laboratories International, Inc. Potentiation of the microbicide 2-(thiocyanomethylthio) benzothiazole using an N-alkyl heterocyclic compound
US6034081A (en) 1995-05-30 2000-03-07 Buckman Laboratories International Inc Potentiation of biocide activity using an N-alkyl heterocyclic compound
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5596878A (en) 1995-06-26 1997-01-28 Thermo King Corporation Methods and apparatus for operating a refrigeration unit
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
FR2749853B1 (fr) 1996-06-12 1998-10-16 Rhone Poulenc Chimie Formulation amelioree a base d'un compose hydroxyle et d'un compose amphiphile complexant utilisable notamment pour modifier les proprietes rheologiques d'emulsions
AU3739697A (en) 1996-07-09 1998-02-02 Johns Hopkins University, The Gene delivery system
AR007855A1 (es) 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
US5948878A (en) 1997-04-15 1999-09-07 Burgess; Stephen W. Cationic polymers for nucleic acid transfection and bioactive agent delivery
JP4503825B2 (ja) 1997-08-27 2010-07-14 カリフォルニア インスティテュート オブ テクノロジー 生物学的組織において癒着の形成を防止するための方法および組成物
US6225346B1 (en) 1997-10-24 2001-05-01 Sugen, Inc. Tyrphostin like compounds
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US7091192B1 (en) 1998-07-01 2006-08-15 California Institute Of Technology Linear cyclodextrin copolymers
WO2000010007A2 (en) 1998-08-17 2000-02-24 California Institute Of Technology Devices and methods for analysis of non-ionic solutes
DE69921158T2 (de) 1998-08-27 2006-01-12 Eidgenössische Technische Hochschule Zürich Gele und mehrschichtige oberflächenstrukturen aus boronsäurehaltigen polymeren
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
PE20011178A1 (es) 2000-04-07 2001-11-19 Takeda Chemical Industries Ltd Compuestos heterociclicos y su produccion
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US6335342B1 (en) 2000-06-19 2002-01-01 Pharmacia & Upjohn S.P.A. Azaindole derivatives, process for their preparation, and their use as antitumor agents
CN1437594A (zh) 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7041280B2 (en) 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
IL160010A0 (en) 2001-07-23 2004-06-20 Univ Ramot Methods and compositions for treating fungal infections
US6737504B2 (en) 2001-07-30 2004-05-18 California Institute Of Technology Synthesis of substituted poly(aniline)s
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
EP1439178A4 (en) 2001-10-05 2005-11-16 Takeda Pharmaceutical Heterocyclic compounds, oxazole derivatives, process for their preparation and their use
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
IL161908A0 (en) 2001-12-12 2005-11-20 Pfizer Prod Inc Quinazoline derivatives for the treatment of abnormal cell growth
CN1608062A (zh) 2001-12-12 2005-04-20 辉瑞产品公司 E-2-甲氧基-n-(3-{4-[3-甲基-4-(6-甲基-吡啶-3-基氧基) -苯氨基]-喹唑啉-6基}-烯丙基)-乙酰胺的盐,其制备和抗癌用途
WO2003053446A1 (en) 2001-12-19 2003-07-03 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US7094427B2 (en) 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
AU2003241898A1 (en) 2002-06-03 2003-12-19 Mitsubishi Pharma Corporation PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
AU2003291567A1 (en) 2002-11-19 2004-06-15 Genzyme Corporation Polymeric boronic acid derivatives as lipase inhibitors
AU2003298749A1 (en) 2002-11-26 2004-06-18 Seacoast Neuroscience, Inc. Buoyant polymer particles delivering therapeutic agents
CN101153042A (zh) 2003-01-29 2008-04-02 武田药品工业株式会社 噻吩并嘧啶化合物及其用途
JP2005119255A (ja) 2003-10-17 2005-05-12 San Quest:Kk 携帯電話画像取り込み機能付き名刺印刷装置
US20050090732A1 (en) 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
US7399645B2 (en) 2004-05-12 2008-07-15 Applera Corporation Constrained cis-diol-borate bioconjugation system
CN101974125B (zh) 2004-07-30 2013-09-18 巴斯夫欧洲公司 聚合物硼酸衍生物及其在造纸中的用途
US7413173B2 (en) 2004-09-10 2008-08-19 Ric Investments, Llc Molded water chamber base plate for use in a humidifier and ventilator assembly
WO2006044275A2 (en) 2004-10-12 2006-04-27 Luminex Corporation Methods for altering surface characteristics of microspheres
TW200618820A (en) 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
PL1866414T3 (pl) 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
EP1893241A2 (en) 2005-04-28 2008-03-05 Ventana Medical Systems, Inc. Fluorescent nanoparticles conjugated to antibodies via a peg linker
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
JP2009508936A (ja) 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー 活性物質の標的化送達用ナノ粒子
US7988988B2 (en) 2005-11-21 2011-08-02 Bausch & Lomb Incorporated Contact lenses with mucin affinity
EP2046266A4 (en) 2006-07-21 2009-11-04 Massachusetts Inst Technology ENDMODICIFIED POLY (BETA AMINO ESTER) AND ITS USE
BRPI0716046A2 (pt) 2006-08-17 2013-09-17 Novartis Ag composiÇÕes de nanopartÍcula.
BRPI0717545A2 (pt) 2006-09-29 2013-10-22 Gezyme Corp Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida
US7825127B2 (en) 2006-12-28 2010-11-02 Takeda Pharmaceutical Company, Limited Method for treating cancer
WO2009036022A1 (en) 2007-09-10 2009-03-19 Board Of Regents, The University Of Texas System Enhancement of polysaccharide-mediated nucleic acid delivery
NZ602302A (en) 2007-12-28 2014-04-30 Impax Laboratories Inc Controlled release formulations of levodopa and uses thereof
US20100029545A1 (en) 2008-08-04 2010-02-04 Sumerlin Brent S Boronic acid-containing block copolymers for controlled drug delivery
ES2915692T3 (es) 2008-08-13 2022-06-24 California Inst Of Techn Nanopartículas portadoras y composiciones, métodos y sistemas relacionados
US8367166B2 (en) 2008-10-31 2013-02-05 Chevron U.S.A. Inc. Synthesis of higher diamondoids
CA2759098A1 (en) 2009-04-14 2010-10-21 Smith Holdings, Llc Methods and compositions for the treatment of medical conditions involving cellular programming
WO2010138193A2 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
FR2946476B1 (fr) 2009-06-05 2014-03-21 Aeg Power Solutions Bv Convertisseur continu-continu a regulation double alternance
US20100330686A1 (en) 2009-06-29 2010-12-30 Seung Bum Park Nanosensor for sugar detection
CN102906127A (zh) 2009-11-06 2013-01-30 华盛顿大学商业中心 来自两性离子聚合物的自组装颗粒以及相关的方法
WO2011072133A1 (en) 2009-12-09 2011-06-16 William Marsh Rice University Therapeutic compositions and methods for delivery of active agents cleavably linked to nanoparticles
WO2011097384A2 (en) 2010-02-04 2011-08-11 Board Of Regents, The University Of Texas System Tumor targeted delivery of immunomodulators by nanoplymers
US20130157926A1 (en) 2010-06-18 2013-06-20 Johannes Franciscus Joseph Engbersen Boronated polymers
US20120225129A1 (en) 2010-08-20 2012-09-06 Cerulean Pharma Inc. Conjugates, particles, compositions, and related methods
US20120148488A1 (en) 2010-12-10 2012-06-14 California Institute Of Technology Targeting Kidney Mesangium With Nanoparticles of Defined Diameter
EP2707419B1 (en) 2011-05-13 2019-08-14 The Regents of The University of California Reversibly crosslinked micelle systems
DE102012017025B4 (de) 2012-08-28 2018-05-30 Kennametal Inc. Werkzeughalter für einen Schneideinsatz und Baugruppe mit einem solchen Werkzeughalter
GB201220474D0 (en) 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
EP2961788B1 (en) * 2013-03-01 2019-05-08 California Institute of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
US9132097B2 (en) 2013-03-01 2015-09-15 California Institute Of Technology Nanoparticles stabilized with nitrophenylboronic acid compositions
ES2986545T3 (es) 2013-03-01 2024-11-11 California Inst Of Techn Nanopartículas dirigidas
US9468681B2 (en) * 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
CA3166758A1 (en) 2013-05-14 2014-11-20 California Institute Of Technology Method of delivering therapeutics and imaging agents by nanoparticles that cross the blood brain barrier
WO2016037166A1 (en) 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
EP3317323B1 (en) 2015-07-01 2021-05-26 California Institute of Technology Cationic mucic acid polymer-based delivery systems

Similar Documents

Publication Publication Date Title
Muthoosamy et al. Graphene and graphene oxide as a docking station for modern drug delivery system
CN103374128B (zh) 两亲性三嵌段共聚物、聚合物纳米载体制剂及制备方法
Metselaar et al. A novel family of L-amino acid-based biodegradable polymer− lipid conjugates for the development of long-circulating liposomes with effective drug-targeting capacity
CN101528815B (zh) 药物复合物用嵌段共聚物及医药组合物
CN103251561B (zh) 一种双敏感可崩解式纳米囊泡药物载体制剂及其制备方法
CN103690961B (zh) 一种智能两亲性聚合物纳米胶束及其制备方法和应用
Bono et al. Role of generation on successful DNA delivery of PAMAM–(Guanidino) Neomycin conjugates
JP2010513526A5 (cg-RX-API-DMAC7.html)
US20140234212A1 (en) Targeted Buccal Delivery of Agents
JP2015519330A5 (cg-RX-API-DMAC7.html)
CN102516552B (zh) 一种可降解的酸敏感高分子两亲性阳离子嵌段共聚物与胶束粒子及其制备方法
CN105997880A (zh) 一种基于交联生物可降解聚合物囊泡的抗肿瘤纳米药物及其制备方法
CN110237035A (zh) 一种主动靶向型两亲性多肽纳米药物载体及其制备与应用
Mignani et al. Dendritic macromolecular architectures: Dendrimer-based polyion complex micelles
CN103421193A (zh) 聚酯酰胺与聚乙二醇嵌段共聚物及其制备方法
Jiang et al. Dendrimer-based nanoparticles in cancer chemotherapy and gene therapy
US9890245B2 (en) Stearic acid derivatives and oleic acid derivatives of multi-arm polyethylene glycol
CN104162166B (zh) pH敏感性多糖纳米载药胶束及其制备方法
KR20080095130A (ko) pH 민감성 블록공중합체를 이용한 약물전달체 제조 및응용
Chen et al. Nonlinear supramolecular polymers for therapeutic applications
Zeng et al. Poly (L-lysine)-based cylindrical copolypeptide brushes as potential drug and gene carriers
Varma et al. Nanoscale dendrimers in targeted drug delivery: a systematic review
Razzazan et al. Influence of PEG molecular weight on the drug release and in vitro cytotoxicity of single-walled carbon nanotubes-PEG-gemcitabine conjugates
V. Theodosopoulos et al. Polymer functionalized graphene oxide: a versatile nanoplatform for drug/gene delivery
Liu et al. Polymer–polymer conjugation to fabricate multi-block polymer as novel drug carriers: Poly (lactic acid)–poly (ethylene glycol)–poly (L-lysine) to enhance paclitaxel target delivery